ESGCT (formerly ESGT) For 14 years, the European Society of Gene Therapy (ESGT) has been actively involved in the evolution of the way we understand and use of gene therapy and cell therapy. Gene therapy has always been intertwined with cell therapy, even as early as in the late 1980s when the field started to emerge. Today our members are engaged in research in these overlapping areas which cannot readily be separated from one another. The members of our Society are leading the world in cutting-edge research and laboratory techniques with gene therapy, hematopoietic, mesenchymal and other stem or progenitor cells, immunotherapies, dendritic cells, NK cells, T cells, pancreatic islets and more. This wide range of target cells reflects a plethora of diseases that are obvious targets for gene and cell therapy, including cancer, diabetes, cardiovascular, neurologic, hereditary and infectious diseases.
ESGT has a new name to reflect these integral changes. The ESGT has become the European Society of Gene and Cell Therapy (ESGCT). The Society facilitates ongoing educational workshops and meetings, supports topical scientific networks and committees, offers a forum for gene therapy, cell therapy and genetic vaccine professionals to interact, and provides a voice in the regulatory arena.
NEWS!European Society of Gene and Cell Therapy is pleased to announce a new partnership with Mary Ann Liebert, Inc., publishers, and has named
Human Gene Therapy as the Official Journal of the Society, with effect from September 1, 2007.
To read more.....
